Clinical trials: Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma, Intrahepatic
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
We aim to explore the effects and safety of GC (Cisplatin and gemcitabine) chemotherapy combined with Lenvatinib as first-line therapy in advanced or unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT04527679
- Testing
- GC combined Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Trial name
- NCT01938729
- Testing
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has…
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer
- Trial name
- NCT02881554
- Testing
- Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan…
- Conditions
- Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT05009953
- Testing
- Irinotecan Liposome Injection, SG001, Fluorouracil
- Where
- China
- Volunteers
- 17 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Cholangiocarcinoma
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
- Trial name
- NCT05348811
- Testing
- HAIC combined with donafenib and sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhongda Hospital
Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
This phase I trial studies the side effects of capecitabine and Y-90 radioembolization in treating patients with bile duct cancer in the liver that has spread to other places in the body and cannot be removed by surgery.
- Conditions
- Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03117855
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Radioembolization
- Where
- United States
- Sponsor
- City of Hope Medical Center
Cholangiocarcinoma Non-resectable
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for…
- Trial name
- CCGLC-013 (NCT06192797)
- Testing
- HAIC, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
The aim of this phase II study is to determine whether pemigatinib is clinically efficious after curative local therapy such as surgery/ SBRT or ablation in iCCA patients harboring FGFR2 fusion/rearrangement and to assess the…
- Conditions
- Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation
- Trial name
- NCT05565794
- Testing
- Pemigatinib
- Where
- 10 sites in Germany
- Volunteers
- 2 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Intrahepatic Cholangiocarcinoma
Liver Transplantation for Early Intrahepatic Cholangiocarcinoma
Diagnosis of intrahepatic cholangiocarcinoma (iCCA) is increasingly common in patients with liver cirrhosis, but these patients are denied liver transplantation (LT) by most centres due to historically poor results.
- Trial name
- LT for iCCA (NCT02878473)
- Testing
- Deceased donor Liver Transplantation
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
- Trial name
- TisGCS for BTC (NCT06903273)
- Testing
- Tislelizumab
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Cheng-Kung University Hospital